Soft tissue sarcoma as a model disease to examine cancer immunotherapy

Current Opinion in Oncology

Volumn 13, Issue 4, 2001, Pages 270-274

  Maki, Robert G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; HYBRID PROTEIN;

AUTOIMMUNE DISEASE; BIOLOGICAL MODEL; CANCER IMMUNOTHERAPY; CHROMOSOME TRANSLOCATION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NEOPLASM; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; TARGET CELL;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; SARCOMA; SOFT TISSUE NEOPLASMS; T-LYMPHOCYTES; TRANSLOCATION, GENETIC;

EID: 0034960246     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200107000-00010     Document Type: Review

References (30)

1. Croonian lecutre on immunity
2. Contribution to the knowledge of sarcoma
3. Surgical management of intra-abdominal desmoid tumours
4. Immunotherapeutic approaches to sarcoma
5. Cancer vaccines
6. Immunity against cancer: Lessons learned from melanoma
7. The use of melanosomal proteins in the immunotherapy of melanoma
8. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas
9. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome
10. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice
11. Serological analysis of human tumor antigens: Molecular definition and implications
12. Induction of primary NY-ESO-1 immunity: CD8+ T-lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
13. Strategy for monitoring T-cell responses to NY-ESO-1 in patients with any HLA class I allele
14. Monitoring CD8 T-cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
15. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients
16. CTL-defined cancer vaccines: Perspectives for active immunotherapeutic interventions in minimal residual disease
17. Mutated mitogen-activated protein kinase: A tumor rejection antigen of mouse sarcoma
18. Cancer-testis antigens: Targets for cancer immunotherapy
19. Expression of MAGE-antigens in normal tissues and cancer
20. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
21. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study
22. Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
23. Tumor rejection antigens of chemically induced sarcomas of inbred mice
24. Heat shock proteins transfer peptides during antigen processing and CTL priming
25. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study
26. Active specific immunotherapy in patients with renal cell carcinoma (RCC) using autologous tumor-derived heat shock protein-peptide complex-96 (HSPPC-96) vaccine
27. Pilot trial of vaccination with autologous tumor-derived gp96 heat shock protein-peptide complex (HSPPC-96) in patients after surgery for gastric carcinoma
28. Pilot trial of vaccination with autologous tumor-derived gp96 heat shock protein-peptide complex (HSPPC-96) in patients with resected pancreatic adenocarcinoma
29. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells
30. Immune surveillance against a solid tumor fails because of immunological ignorance